subject area of
- An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001 Academic Article
- Bilateral knee osteonecrosis in a patient with thrombotic thrombocytopenic purpura Academic Article
- Bisphosphonate Associated Osteonecrosis of the Jaw Academic Article
- Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus Academic Article
- Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Academic Article
- Impact of selective alveolar decortication on bisphosphonate burdened alveolar bone during orthodontic tooth movement Academic Article
- Insufficient evidence of superiority of any treatment for medication-related osteonecrosis of the jaw Academic Article
- Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis Academic Article
- Osteonecrosis in children and adolescents with cancer Academic Article
- Osteonecrosis in children and adolescents with cancer – An adverse effect of systemic therapy Academic Article
- Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 Academic Article
- Reducing bladder artifacts in clinical pelvic SPECT images. Academic Article
- Resolution of Osteonecrosis of the Jaw After Teriparatide [Recombinant Human PTH-(1-34)] Therapy Academic Article
- Steroid-Induced Osteonecrosis in Dermatology Academic Article
- The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw Academic Article
- The development of thromboembolism may increase the risk of osteonecrosis in children with acute lymphoblastic leukemia Academic Article
- Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease Academic Article